advertisement
Hu Y 23
Showing records 1 to 23 | Display all abstracts from Hu Y98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Fang F
Molecular Therapy 2022; 30: 1421-1431
98269 Measures of disease activity in glaucoma
Wu Y
Biosensors & bioelectronics 2022; 196: 113700
98642 TGF-β2-induced circ-PRDM5 regulates migration, invasion, and EMT through the miR-92b-3p/COL1A2 pathway in human lens epithelial cells
Huang P
Journal of molecular histology 2022; 53: 309-320
99075 Long-term visual outcomes of primary congenital glaucoma in China
Fang L
Ophthalmic Research 2022; 0:
98269 Measures of disease activity in glaucoma
Szymanska M
Biosensors & bioelectronics 2022; 196: 113700
99075 Long-term visual outcomes of primary congenital glaucoma in China
Hu Y
Ophthalmic Research 2022; 0:
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Zhuang P
Molecular Therapy 2022; 30: 1421-1431
98642 TGF-β2-induced circ-PRDM5 regulates migration, invasion, and EMT through the miR-92b-3p/COL1A2 pathway in human lens epithelial cells
Hu Y
Journal of molecular histology 2022; 53: 309-320
98269 Measures of disease activity in glaucoma
Hu Y
Biosensors & bioelectronics 2022; 196: 113700
98642 TGF-β2-induced circ-PRDM5 regulates migration, invasion, and EMT through the miR-92b-3p/COL1A2 pathway in human lens epithelial cells
Duan Y
Journal of molecular histology 2022; 53: 309-320
99075 Long-term visual outcomes of primary congenital glaucoma in China
Zhong Y
Ophthalmic Research 2022; 0:
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Feng X
Molecular Therapy 2022; 30: 1421-1431
99075 Long-term visual outcomes of primary congenital glaucoma in China
Xiao H
Ophthalmic Research 2022; 0:
98269 Measures of disease activity in glaucoma
Fazal MI
Biosensors & bioelectronics 2022; 196: 113700
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Liu P; Liu D
Molecular Therapy 2022; 30: 1421-1431
98269 Measures of disease activity in glaucoma
Jiang N
Biosensors & bioelectronics 2022; 196: 113700
99075 Long-term visual outcomes of primary congenital glaucoma in China
Lin S; Zhu Y
Ophthalmic Research 2022; 0:
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Huang H
Molecular Therapy 2022; 30: 1421-1431
98269 Measures of disease activity in glaucoma
Yetisen AK; Cordeiro MF
Biosensors & bioelectronics 2022; 196: 113700
99075 Long-term visual outcomes of primary congenital glaucoma in China
Su Y
Ophthalmic Research 2022; 0:
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Li L; Chen W
Molecular Therapy 2022; 30: 1421-1431
99075 Long-term visual outcomes of primary congenital glaucoma in China
Liu X
Ophthalmic Research 2022; 0:
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Liu L; Sun Y; Jiang H; Ye J; Hu Y
Molecular Therapy 2022; 30: 1421-1431
